Alpha Teknova Q2 revenue beats estimates

Alpha Teknova

07/08/2025 21:23

Overview

Alpha Teknova Q2 revenue rises 7% yr/yr, beating analyst expectations

Company achieves four consecutive quarters of revenue growth

Teknova reaffirms 2025 revenue guidance of $39-42 mln

Outlook

Alpha Teknova reaffirms 2025 revenue guidance of $39-42 mln

Company anticipates 2025 free cash outflow under $12 mln

Alpha Teknova expects sustainable growth despite macroeconomic uncertainties

Result Drivers

MANUFACTURING EFFICIENCY - Gross margin improved to 38.7% from 29.2% due to manufacturing efficiency gains and higher revenue

CLINICAL SOLUTIONS GROWTH - Revenue in Clinical Solutions segment increased by 32%, contributing to overall revenue growth

COST MANAGEMENT - Operating expenses decreased due to reduced spending on insurance and facility costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$10.29 mln
$9.91 mln (5 Analysts)
Q2 EPS
-$0.07
Q2 Net Income
-$3.57 mln
Q2 Free Cash Flow
-$2.30 mln
Q2 Gross Profit
$3.98 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Alpha Teknova Inc is $11.00, about 60.5% above its August 6 closing price of $4.35

Press Release: ID:nGNX350Mzd

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)